

Contents lists available at [ScienceDirect](http://ScienceDirect.com)

Autoimmunity Reviews

journal homepage: www.elsevier.com/locate/autrev

Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis

Péter Szodoray^a, Zoltán Szabó^b, Anikó Kapitány^c, Ágnes Gyetvai^c, Gabriella Lakos^c, Sándor Szántó^b, Gabriella Szücs^b, Zoltán Szekanecz^{b,*}

^a Immunobiological Laboratory, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway

^b Department of Rheumatology, Institute of Medicine, University of Debrecen Medical and Health Science Center, Debrecen, Hungary

^c Laboratory of Immunology, Institute of Medicine, University of Debrecen Medical and Health Science Center, Debrecen, Hungary

ARTICLE INFO

Article history:

Received 15 April 2009

Accepted 30 April 2009

Available online xxxxx

Keywords:

Rheumatoid arthritis

ACPA

Anti-CCP

HLA-DR

Shared epitope

Genetics

Autoimmunity

ABSTRACT

Anti-citrullinated protein/peptide antibodies (ACPA) have recently emerged as sensitive and specific serological markers of rheumatoid arthritis (RA), providing superior alternative of the rheumatoid factor (RF) test in the laboratory diagnostics of RA. Citrullination is a post-translational modification of arginine by deimination, physiologically occurring during apoptosis, inflammation or keratinization. The presence of several citrullinated proteins has been demonstrated in the RA synovium. The identification of citrullinated epitopes as targets led to the development of the first and later second-generation anti-cyclic citrullinated peptide (anti-CCP) antibody assays. The anti-Sa antibody has been identified a decade ago; however, recent studies confirmed that anti-Sa is directed against citrullinated vimentin. The determination of ACPA may have important prognostic significance, since ACPA production can precede the onset of clinical RA symptoms by years. ACPA⁺ individuals with early, undifferentiated arthritis may have higher risk to develop RA. ACPA has important prognostic role during the progression of RA and it has also been associated with pronounced radiographic progression. ACPA production has been associated with several genetic predisposing factors, including HLA-DRB1 and PTPN22 1858T alleles, as well as with environmental and lifestyle-related factors, primarily smoking and possibly, the use of oral contraceptives and excessive caffeine intake. Thus, the assessment of ACPA, in addition to clinical, radiographic and genetic outcome measures may be important to assess disease prognosis and aids to design effective, early therapeutic strategies.

© 2009 Elsevier B.V. All rights reserved.

Contents

1. Introduction	00
2. Anti-citrullinated protein/peptide antibodies	00
2.1. Synovial citrullination and production of ACPA	00
2.2. Predictive value of ACPA	00
2.3. ACPA as prognostic marker	00
3. Prognostic value of genetic factors	00
3.1. MHC genes as outcome measures	00
3.2. The prognostic value of non-MHC genes	00
4. Environmental and lifestyle-associated prognostic factors	00
5. Conclusion	00
Take-home messages	00
References	00

1. Introduction

Rheumatoid arthritis (RA) is an autoimmune-inflammatory disease that may lead to joint destruction and disability [1]. Genetic factors including class II major histocompatibility complex (MHC) and

* Corresponding author. Department of Rheumatology, Institute of Medicine, University of Debrecen Medical and Health Science Center, 98 Nagyerdei str, Debrecen, H-4012, Hungary. Tel.: +36 52 xxx 091; fax: +36 52 414 489.

E-mail address: szekanecz.zoltan@med.unideb.hu (Z. Szekanecz).

non-MHC alleles, environmental factors and autoimmune processes are highly involved in the pathogenesis of RA [2]. Early diagnosis and immediate, effective therapy are crucial in order to prevent joint deterioration, functional disability and unfavorable disease outcome [1,3]. Currently, optimal management of RA is needed within 3–6 months after the onset of disease, therefore a very narrow “window of opportunity” is present to achieve remission [3]. Thus, reliable outcome measures are needed in order to establish prognosis early and to conduct good clinical practice.

Significant amount of data have become available suggesting that genetic factors and autoimmune-inflammatory markers are good indicators of outcome [2,4]. In this review, we aim to summarize recent data regarding the predictive and prognostic value of genetic and laboratory markers in RA.

2. Anti-citrullinated protein/peptide antibodies

2.1. Synovial citrullination and production of ACPA

Citrulline is the post-translationally modified, deiminated derivative of arginine [4,5]. The arginine-to-citrulline transition is catalyzed by the peptidylarginine-deiminase (PAD) enzyme that has five isoforms in mammals, PAD1–4 and PAD6 [5,6]. Tissue citrullination is a physiological process underlying epithelial keratinization, inflammation and increased apoptosis [4–7]. Inflammatory leukocytes including RA synovial T and B cells, macrophages, neutrophils and synovial fibroblasts express both the PAD2 and PAD4 isoforms [4,6,8]. There is relatively small amount of citrullinated proteins in the normal synovial tissue, whereas active citrullination has been associated with synovitis [6–8]. Citrullinated protein epitopes have been identified in extravascular fibrin deposits and extracellular fibrinogen aggregates within the RA synovium [6,7]. Filaggrin, the first citrullinated protein identified, as potential autoantigen in RA is an epidermal protein usually absent from the synovium [9]. Thus, other citrullinated proteins, such as fibrin or vimentin that are abundantly expressed and citrullinated in synovial tissues may drive autoantibody responses [8–12]. Indeed, citrullinated fibrin (CF) has been detected in RA synovial fluid [12], whereas citrullinated vimentin is expressed by synovial macrophages [10,13]. These autoantigens induce the production of anti-citrullinated protein/peptide autoantibodies (ACPA) that have been associated with autoimmunity underlying RA [4,8,13,14]. *In vivo*, deiminated α and β chains of fibrin may be the dominant autoantigen in RA, while other citrullinated proteins may cross-react with CF during antibody production [15]. Although, most studies suggest high diagnostic specificity and sensitivity of ACPAs in RA [4,8,10,16], tissue citrullination and ACPA production have been detected in patients with other types of arthritis, yet less frequently [16,17]. In comparative studies, 74–97% of RA, but only 6–7% of psoriatic arthritis (PsA) patients were anti-cyclic citrullinated peptide (anti-CCP) positive [16,17].

2.2. Predictive value of ACPA

Patients presenting with undifferentiated polyarthritis (UDP) may eventually develop definitive RA, remain UDP for years, or may undergo spontaneous remission [3]. Identifying biomarkers, suggesting the transition of UDP to RA are of utmost importance [3,18]. ACPA may be detected in the sera of patients years before the onset of clinical symptoms [4,19]. In the preclinical phase, 25% of patients, who develop RA later than 18 months, while 52% of those that develop RA within 18 months are anti-CCP positive [19]. The positive ACPA serology may predict the development of RA in patients with UDP [3,19].

2.3. ACPA as prognostic marker

Regarding its prognostic value in established RA, ACPA seropositivity has been associated with a more severe, destructive disease

course [4,8,19,20]. ACPA⁺ RA patients developed more erosions after 6–10 years of follow-up [3,18]. Seropositivity has also been associated with sustained inflammatory activity indicated by long-term elevation of erythrocyte sedimentation rate (ESR) and disease activity score (DAS)28 [18,20]. Among various ACPAs, these associations could be confirmed regarding anti-CCP, anti-mutated citrullinated vimentin (MCV), as well as anti-CF [4,10,15,16,19,20].

In an early study, the prognostic value of anti-perinuclear factor (APF) determined by indirect immunofluorescence was assessed in patients with early RA (duration <1 year). APF had additional value in differentiating RF⁺ and RF⁻ patients with respect to radiographic damage [21]. In an inception cohort of 273 patients with RA (disease duration <1 year), anti-CCP⁺ patients developed more severe joint destruction after 6 years of follow-up. While radiographic damage was predicted by both ACPA and IgM RF at baseline, functional deterioration was predicted only by RF at entry [22]. In early RA, ACF antibodies also had good prognostic value for radiographic progression after 2 years [8,15]. When serial determination of anti-CCP was performed in 99 early RA patients at baseline and subsequently, within the first 3 years, anti-CCP positivity was associated with 5-year progression of the total Sharp score (OR 3.2), erosion score (OR 5.3) and joint space narrowing score (OR 2.8). In addition, anti-CCP⁻ patients had less radiographic progression than those with increasing anti-CCP production [23]. The prognostic value of ACPA has also been confirmed in very early RA (duration <3 months) [24].

When four outcome measures were compared with respect to prognostic value for joint destruction after 10 years, anti-CCP was the best indicator (OR 4.0), while the other three indicators (female sex, ESR and RF) showed less potential (OR 3.1–3.3) [25]. Similarly, when anti-CCP and RF were compared with respect to severity of structural damage in the Norfolk Arthritis Register, anti-CCP⁺ at baseline was strongly associated with both prevalent erosions (OR 2.5) and developing erosions after 5 years (OR 10.2). Anti-CCP exerted better performance than IgM RF (OR 1.6 and 3.4, respectively) [26]. In another comparative study, anti-CCP had higher positive predictive value for erosive RA than RF, C-reactive protein (CRP), ESR or matrix metalloproteinase-3 (MMP-3) [27].

3. Prognostic value of genetic factors

3.1. MHC genes as outcome measures

Certain HLA-DRB1*01 (HLA-DR1) and HLA-DRB1*04 (HLA-DR4) alleles, also known as “shared epitopes” (SE), has been associated with susceptibility to and/or progression of RA [2,28–30]. SE is a risk factor for more severe, destructive RA, as well as for the development of extraarticular manifestations [2,28]. It is likely, that the SE itself may not be directly responsible for poorer prognosis, but it may rather influence outcome indirectly, via ACPA production [2,4,31]. Indeed, SE is probably the primary risk factor for increased ACPA production in RA [4,28,29,31,32]. SE was not only associated with positive ACPA titers, but also with absolute serum ACPA levels [29]. Among HLA-DRB1 alleles, ACPA production has been associated with HLA-DRB1*04, rather than HLA-DRB1*01 [2,11,29]. Among HLA-DRB1*04 subtypes, DRB1*0401, *0404, *0405 and *0408 SE exerted the closest association with positive ACPA [2,33]. In a recently published study, among 2221 single-nucleotide polymorphisms (SNPs) within the MHC region, 299 SNPs showed significant associations with ACPA⁺ RA, while none of these SNPs could be associated with seronegative RA [34]. Among non-SE HLA-DRB1 alleles, HLA-DRB1*13 and DRB1*15 have also been implicated in ACPA production [29]. Regarding various ACPAs, positive SE has been associated with anti-CCP, anti-CV and anti-CF production [2,4,8,15,33,35]. In contrast, HLA-DRB*03 (HLA-DR3) may rather be associated with ACPA⁻ RA and milder disease course [2].

187 3.2. The prognostic value of non-MHC genes

188 Regarding non-HLA genes, the 1858C/T allele (rs2476601) poly-
189 morphism of PTPN22 has been associated with anti-CCP⁺ and RF⁺ RA
190 [30,36,37]. This has also been confirmed in UDP and early RA [37].

191 Fcγ receptors are key players in antigen presentation and inflam-
192 mation. In a cohort of 945 RA patients, Fcγ receptor IIIA (FcγRIIIA)
193 158V/F polymorphism was assessed and the VV genotype showed
194 clear association with ACPA⁺ RA [38].

195 In conclusion, SE, possibly other MHC genes including HLA-DRB1*13
196 and DRB1*15, and non-MHC genes including PTPN22-1858C/T
197 and FcγRIIIA-158V/F alleles are associated with ACPA production and
198 thus, they may serve as indirect outcome measures. The use of multiple
199 indices, such as HLA-DRB1 + PTPN22 + ACPA may exert even higher
200 prognostic value. In contrast, HLA-DRB1*03 may confer ACPA serone-
201 gativity and better prognosis. However, there may be geographical
202 differences in the prognostic value of genetic factors described above
203 [2,11,29,30,32,33,35–38].

204 Regarding the comparison between genetic and immunological
205 markers as outcome measures, ACPA may have better predictive/
206 prognostic value than SE or PTPN22 polymorphism [30].

207 4. Environmental and lifestyle-associated prognostic factors

208 Numerous studies have been performed with respect to the role
209 of environmental and lifestyle-related factors, primarily smoking,
210 in susceptibility to the development and progress of RA. At least in
211 some geographical regions, smoking has been associated with the
212 development of extraarticular manifestations, including nodulosis
213 and cardiovascular complications, as well as with more progressive
214 disease course [33,39,40]. Yet, smoking may not be related to radio-
215 graphic progression [39]. It is likely, that smoking forms a “Bermuda
216 triangle” with SE and ACPA. Smoking promotes the citrullination of
217 synovial proteins and thus ACPA production [33,39]. In Scandinavian,
218 Dutch and French cohorts, a high risk for the development of ACPA⁺
219 RA was observed in patients carrying one or two SE alleles [33,39,40].
220 In SE⁺ patients, smoking is not only associated with positive ACPA, but
221 also with absolute serum anti-CCP levels [33]. While, as described
222 above, primarily HLA-DRB1*04 alleles have been associated with
223 ACPA production [2,11,29], in smokers, HLA-DRB1*0101, *0102 and
224 *1001 alleles showed the closest association with positive anti-CCP
225 [33]. Smoking confers increased disease progression [39,40].

226 Regarding other environmental factors, based on studies, con-
227 ducted in Scandinavian cohorts, higher body weight at birth, the use of
228 oral contraceptives and excessive caffeine consumption (>10/day)
229 conferred higher risk to develop ACPA⁺ RA. Interestingly, obesity was
230 associated with higher risk to seronegative RA. Red meat, vitamin D
231 and estrogen intake may be neutral in this respect, while moderate
232 wine consumption may decrease susceptibility [39,40]. In a Danish
233 cohort, SE⁺ heavy coffee drinkers had 53-times, contraceptive users
234 had 45-times higher risk to develop anti-CCP⁺ RA [40].

235 5. Conclusion

236 In conclusion, RA patients may be classified into ACPA⁺ and ACPA⁻
237 subpopulations that may have important prognostic significance. The
238 terms “seropositive” and “seronegative”, originally based on the
239 evaluation of IgM RF, have undergone major transition. The develop-
240 ment of ACPA may precede the onset of clinical symptoms by years.
241 ACPA has predictive role in early, undifferentiated arthritis and ACPA⁺
242 individuals with UDP may have higher risk to develop RA. ACPA has
243 important prognostic role during the progression of RA and it is also
244 associated with more pronounced structural damage of the joints
245 indicated by radiographic progression. ACPA production has been
246 associated with certain genetic makeup, including the presence of SE,
247 or PTPN22 gene polymorphisms, as well as with environmental and

lifestyle-related factors. Individuals carrying SE, or the PTPN22 1858T
248 allele, in addition to smoking exert increased radiographic progression
249 and unfavorable prognosis. Other factors, such as the use of oral
250 contraceptives, or excessive caffeine intake may also have relevance for
251 the development of ACPA⁺ RA. In clinical practice, a combination of
252 autoantibodies and genetic factors, in addition to clinical and radio-
253 graphic outcome measures should be determined in order to better
254 assess the outcome of RA and to enable optimal, early treatment. 255

256 Take-home messages

- Synovial citrullination and the production of ACPA are crucial for the 258 pathogenesis and prognosis of rheumatoid arthritis. 259
- ACPA production has been associated with genetic factors including 260 the shared epitope, PTPN22 polymorphism, as well as with lifestyle- 261 related factors, primarily, smoking. 262
- The determination of ACPA in association with genetic and environ- 263 mental factors at the onset of the disease may serve as a complex 264 outcome measure in RA. 265 266

267 References

- [1] Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. *Autoimmun Rev* 2005;4(3):130–6. 269
- [2] van der Helm-van Mil AH, Wesely JZ, Huizinga TW. Understanding the genetic 271 contribution to rheumatoid arthritis. *Curr Opin Rheumatol* 2005;17(3):299–304. 272
- [3] Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid 273 arthritis. *Best Pract Res Clin Rheumatol* 2006;20(5):849–63. 274
- [4] Klareskog L, Widhe M, Hermansson M, Ronnelid J. Antibodies to citrullinated 275 proteins in arthritis: pathology and promise. *Curr Opin Rheumatol* 2008;20 276 (3):300–5. 277
- [5] Suzuki A, Yamada R, Yamamoto K. Citrullination by peptidylarginine deiminase in 278 rheumatoid arthritis. *Ann N Y Acad Sci* 2007;1108:323–39. 279
- [6] Vossenaar ER, Radstake TR, van der Heijden A, van Mansum MA, Dieteren C, de 280 Rooij DJ, et al. Expression and activity of citrullinating peptidylarginine deiminase 281 enzymes in monocytes and macrophages. *Ann Rheum Dis* 2004;63(4):373–81. 282
- [7] Sebbag M, Chapuy-Regaud S, Auger I, Petit-Texeira E, Clavel C, Nogueira L, et al. Clinical 283 and pathophysiological significance of the autoimmune response to citrullinated 284 proteins in rheumatoid arthritis. *Joint Bone Spine* 2004;71(6):493–502. 285
- [8] Szekanecz Z, Soos L, Szabo Z, Fekete A, Kapitany A, Vegvari A, et al. Anti- 286 citrullinated protein antibodies in rheumatoid arthritis: as good as it gets? *Clin Rev 287 Allergy Immunol* 2008;34(1):26–31. 288
- [9] Simon M, Girbal E, Sebbag M, Gomes-Daudrix V, Vincent C, Salama G, et al. The 289 cytokeratin filament-aggregating protein filaggrin is the target of the so-called 290 “antikeratin antibodies,” autoantibodies specific for rheumatoid arthritis. *J Clin 291 Invest* 1993;92(3):1387–93. 292
- [10] Soos L, Szekanecz Z, Szabo Z, Fekete A, Zeher M, Horvath IF, et al. Clinical 293 evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. 294 *J Rheumatol* 2007;34(8):1658–63. 295
- [11] Snir O, Widhe M, von Spee C, Lindberg J, Padyukov L, Lundberg K, et al. Multiple 296 antibody reactivities to citrullinated antigens in sera from patients with rheu- 297 matoid arthritis: association with HLA-DRB1 alleles. *Ann Rheum Dis* 2009;68(5): 298 736–43. 299
- [12] Takizawa Y, Suzuki A, Sawada T, Ohsaka M, Inoue T, Yamada R, et al. Citrullinated 300 fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis 301 synovial fluids. *Ann Rheum Dis* 2006;65(8):1013–20. 302
- [13] Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T, et al. 303 Rheumatoid arthritis specific anti- α antibodies target citrullinated vimentin. 304 *Arthritis Res Ther* 2004;6(2):R142–50. 305
- [14] Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, 306 et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a 307 cyclic citrullinated peptide. *Arthritis Rheum* 2000;43(1):155–63. 308
- [15] Sebbag M, Moinard N, Auger I, Clavel C, Arnaud J, Nogueira L, et al. Epitopes of 309 human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to 310 citrullinated proteins. *Eur J Immunol* 2006;36(8):2250–63. 311
- [16] Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij WJ, Tak PP. The 312 presence of citrullinated proteins is not specific for rheumatoid synovial tissue. 313 *Arthritis Rheum* 2004;50(11):3485–94. 314
- [17] Alenius GM, Berglin E, Rantapaa Dahlqvist S. Antibodies against cyclic citrullinated 315 peptide (CCP) in psoriatic patients with or without joint inflammation. *Ann 316 Rheum Dis* 2006;65(3):398–400. 317
- [18] Nell VP, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, et al. Autoantibody 318 profiling as early diagnostic and prognostic tool for rheumatoid arthritis. *Ann 319 Rheum Dis* 2005;64(12):1731–6. 320
- [19] van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibody, a marker for the early 321 detection of rheumatoid arthritis. *Ann N Y Acad Sci* 2008;1143:268–85. 322
- [20] Skogh T. Does a positive anti-CCP test identify a distinct arthritis entity? *Arthritis 323 Res Ther* 2005;7(6):230–2. 324

- 325 [21] van Jaarsveld CH, ter Borg EJ, Jacobs JW, Schellekens GA, Gmelig-Meyling FH, van
326 Booma-Frankfort C, et al. The prognostic value of the antiperinuclear factor, anti-
327 citrullinated peptide antibodies and rheumatoid factor in early rheumatoid
328 arthritis. *Clin Exp Rheumatol* 1999;17(6):689–97.
- 329 [22] Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M,
330 et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients
331 with recent-onset rheumatoid arthritis. *Arthritis Rheum* 2000;43(8):1831–5.
- 332 [23] Meyer O, Nicaise-Roland P, Santos MD, Labarre C, Dougados M, Goupille P, et al.
333 Serial determination of cyclic citrullinated peptide autoantibodies predicted five-
334 year radiological outcomes in a prospective cohort of patients with early
335 rheumatoid arthritis. *Arthritis Res Ther* 2006;8(2):R40.
- 336 [24] Nell-Duxneuner V, Machold K, Stamm T, Eberl G, Heinzl H, Hoeffler E, et al.
337 Autoantibody profiling in patients with very early rheumatoid arthritis – a follow-
338 up study. *Ann Rheum Dis* 2009.
- 339 [25] Syversen SW, Gaarder PI, Goll GL, Odegard S, Haavardsholm EA, Mowinckel P, et al.
340 High anti-cyclic citrullinated peptide levels and an algorithm of four variables
341 predict radiographic progression in patients with rheumatoid arthritis: results
342 from a 10-year longitudinal study. *Ann Rheum Dis* 2008;67(2):212–7.
- 343 [26] Bukhari M, Thomson W, Naseem H, Bunn D, Silman A, Symmons D, et al. The
344 performance of anti-cyclic citrullinated peptide antibodies in predicting the
345 severity of radiologic damage in inflammatory polyarthritis: results from the
346 Norfolk Arthritis Register. *Arthritis Rheum* 2007;56(9):2929–35.
- 347 [27] Shovman O, Gilburd B, Zandman-Goddard G, Sherer Y, Orbach H, Gerli R, et al. The
348 diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metallo-
349 proteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive
350 protein in patients with erosive and non-erosive rheumatoid arthritis. *Clin Dev
351 Immunol* 2005;12(3):197–202.
- 352 [28] Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van Gaalen FA,
353 Jawaheer D, et al. Refining the complex rheumatoid arthritis phenotype based on
354 specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins.
355 *Arthritis Rheum* 2005;52(11):3433–8.
- 356 [29] Kapitany A, Szabo Z, Lakos G, Aleksza M, Vegvari A, Soos L, et al. Associations
357 between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4
358 expression in Hungarian patients with rheumatoid arthritis. *Isr Med Assoc J*
359 2008;10(1):32–6.
- 360 [30] Goeb V, Dieude P, Daveau R, Thomas-Lotellier M, Jouen F, Hau F, et al. Contribution
361 of PTPN22 1858T, TNFR11 196R and HLA-shared epitope alleles with rheumatoid
362 factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis
363 diagnosis. *Rheumatology (Oxford)* 2008;47(8):1208–12.
- 364 [31] de Vries RR, Huizinga TW, Toes RE. Redefining the HLA and RA association: to be or
365 not to be anti-CCP positive. *J Autoimmun* 2005;25:21–5 [Suppl].
- 366 [32] Poor G, Nagy ZB, Schmidt Z, Brozik M, Meretey K, Gergely Jr P. Genetic background
367 of anticyclic citrullinated peptide autoantibody production in Hungarian patients
368 with rheumatoid arthritis. *Ann N Y Acad Sci* 2007;1110:23–32.
- 369 [33] van der Helm-van Mil AH, Verpoort KN, le Cessie S, Huizinga TW, de Vries RR, Toes
370 RE. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking
371 and predisposition to antibodies to cyclic citrullinated peptide. *Arthritis Rheum*
372 2007;56(2):425–32.
- 373 [34] Ding B, Padyukov L, Lundstrom E, Seielstad M, Plenge RM, Oksenberg JR, et al. 373
374 Different patterns of associations with anti-citrullinated protein antibody-positive
375 and anti-citrullinated protein antibody-negative rheumatoid arthritis in the
376 extended major histocompatibility complex region. *Arthritis Rheum* 2009;60
377 (1):30–8.
- 378 [35] Verpoort KN, Cheung K, Ioan-Facsinay A, van der Helm-van Mil AH, de Vries-
379 Bouwstra JK, Allaart CF, et al. Fine specificity of the anti-citrullinated protein
380 antibody response is influenced by the shared epitope alleles. *Arthritis Rheum* 380
2007;56(12):3949–52.
- 381 [36] Farago B, Talian GC, Komlosi K, Nagy G, Berki T, Gyetvai A, et al. Protein tyrosine
382 phosphatase gene C1858T allele confers risk for rheumatoid arthritis in Hungarian
383 subjects. *Rheumatol Int* 2008.
- 384 [37] Feitsma AL, Toes RE, Begovich AB, Chokkalingam AP, de Vries RR, Huizinga TW,
385 et al. Risk of progression from undifferentiated arthritis to rheumatoid arthritis:
386 the effect of the PTPN22 1858T-allele in anti-citrullinated peptide antibody
387 positive patients. *Rheumatology (Oxford)* 2007;46(7):1092–5.
- 388 [38] Thabet MM, Huizinga TW, Marques RB, Stoeken-Rijsbergen G, Bakker AM,
389 Kurreeman FA, et al. The contribution of Fc gamma receptor IIIA gene 158V/F
390 polymorphism and copy number variation to the risk of ACPA positive rheumatoid
391 arthritis. *Ann Rheum Dis* 2008.
- 392 [39] Klareskog L, Padyukov L, Lorentzen J, Alfredsson L. Mechanisms of disease: Genetic
393 susceptibility and environmental triggers in the development of rheumatoid
394 arthritis. *Nat Clin Pract Rheumatol* 2006;2(8):425–33.
- 395 [40] Pedersen M, Jacobsen S, Garred P, Madsen HO, Klarlund M, Svejgaard A, et al. 396
397 Strong combined gene-environment effects in anti-cyclic citrullinated peptide-
398 positive rheumatoid arthritis: a nationwide case-control study in Denmark.
399 *Arthritis Rheum* 2007;56(5):1446–53.